Placental Adaptation to Hypoxia as a Predictive Marker for Preeclampsia by Ahmed, Sarah I.Y.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Placental Adaptation to Hypoxia 
as a Predictive Marker for 
Preeclampsia
Sarah I.Y. Ahmed
Abstract
The ability of the placenta to interact with surrounding microenvironment of 
hypoxia can serve as a predictive marker for the development of preeclampsia. 
Lessons can be studied from highlands inhabitants and their ability to survive 
extreme conditions of hypobaric hypoxia. Many candidate genes loci that are 
associated with adaptation to high altitude hypoxia and healthy exercise are also 
associated with adaptation to hypoxia in normal pregnancy. This can pave the way 
to a new approach based on the concept of evolution and adaptation stating that 
“genes can undergo a process of natural selection for the fittest adaptive variants, so 
as to reach a state of adaptation to the scarce microenvironments.” Accordingly, the 
degree of adaptation in candidate genes and their polymorphisms can serve as pre-
dictive markers for the development of preeclampsia. This can be seen in the high 
degree of concordance between gene expression and the lesions seen in the placenta 
and other remote organs in the different subtypes of preeclampsia. To conclude, 
“adaptive or less adaptive” can be the genetic result that answers the question of 
disease prediction, recurrence, and possible complications.
Keywords: placenta, adaptation, hypoxia, predictive marker
1. Introduction
Throughout the lives of individuals, their genes interact with their environments 
to cause variations in phenotype traits. Because individuals with certain traits tend 
to survive and reproduce more than others with less successful traits, the population 
evolves. In 1859, Charles Darwin set out his theory of evolution by natural selection 
as an explanation for adaptation and speciation. He defined natural selection as the 
“principle by which each slight variation [of a trait], if useful, is preserved” [1]. 
Although the Darwinian theory was ages before the genome era, it can also explain 
the process of natural selection at molecular levels; cells with successful traits are 
best adapted to their microenvironments, and more likely to survive and proliferate. 
The selection between cells favors those with the most advantageous genetic poly-
morphisms. The genetic variability is usually enhanced by the scarce microenviron-
ments like low oxygen, low temperature, and high radiation that act as competitive 
milieus for cells. The useful genetic variants are preserved and can be heritable.
Some 2.4 billion years ago, photosynthesis leads to the accumulation of oxygen 
to levels that were likely toxic to many microorganisms. Organisms that could 
Prediction of Maternal and Fetal Syndrome of Preeclampsia
2
defend themselves against oxidative stress and at the same time utilize oxygen for 
energy, survived and evolved. As time went on, cellular requirement for oxygen 
became critical, and animals developed a physiological response to the low levels of 
oxygen. The cellular ability to compete in such scarce microenvironments became 
the “microevolutionary” exam for survival in many physiological processes as in 
hematopoiesis, spermatogenesis, normal pregnancy, and embryogenesis. Genetic 
studies suggest that hypoxia-inducible factors (HIFs) are a family of master tran-
scriptional regulators for the hypoxic response inside the body. HIF-α transcription 
factors (HIF-1α and HIF-2α/EPAS1) dimerize with HIF-1β/ARNT subunits, and 
translocate to the nucleus, where it binds to the hypoxia responsive element (HRE) 
in the genetic material to regulate the transcription of some 200 genes, leading to 
the adaptive response to hypoxic stress. In turn, hypoxia responsive genes promote 
the tolerance of hypoxia by decreasing the cellular requirement for oxygen and 
increasing the supply of oxygen. They mainly involved in angiogenesis, erythropoi-
esis, energy metabolism, and autophagy [2].
On ascent to high attitudes, lowlanders become at risk of conditions like acute 
mountain sickness (AMS), pulmonary edema, cerebral edema, and polycythemia in 
the chronic type of the disease. These conditions, which resemble many symptoms 
associated with preeclampsia, are considered to be a maladaptive response to the 
low oxygen levels at high altitudes. However, ancient indigenous populations like 
Tibetans through generations acquired unique integrated physiological processes 
for defending their body against oxygen deprivation. This gives them the advantage 
of being protected from hypoxia-related disorders, like hypertension, diabetes 
mellitus, cardiovascular disorders, and preeclampsia. Yet, physiological acclimati-
zation can occur in lowlanders over days to weeks following ascent and can serve as 
the first steps of adaptation. This led to the idea that adaptation to hypoxia can also 
protect from pathological disorders that result in dysregulation of hypoxia pathways 
like in preeclampsia [3].
2. Preeclampsia as a maladaptive disorder
In spite of the extensive research in the pathophysiology of the disease, the 
etiology is still poorly understood. It was suggested to be due to the insufficient 
adaptation of spiral arterioles or due to the shallow trophoblastic invasion, resulting 
in reduced uteroplacental blood flow leading to placental hypoxia. The placenta 
initially develops in a low oxygen environment of 1–2% oxygen until after the 
10th week of pregnancy. This maternal hypoxia is an effective stimulus eliciting 
adaptations at the maternal-fetal interface, which include activation of the invasive 
endovascular trophoblast cell lineage and modifications of uterine blood vessels 
supplying the developing chorioallantoic placenta. Reduced or absent cytotro-
phoblast invasion of the maternal uterine spiral arterioles is a common clinical 
finding in studies of pregnancies complicated by preeclampsia, suggesting that the 
mechanism mediating invasion of these cells is perturbed. While, it is proposed that 
hypoxia-inducible factors are the key regulators of the first trimester [4–7].
The exposure of pregnant women to hypobaric hypoxia at high altitudes leads 
to arterial maternal hypoxia and intervillous blood hypoxia at the maternal-fetal 
interface. This renders pregnant women from low-altitude to be at risk of many 
complications including reproductive loss, intrauterine growth restriction, and 
preeclampsia. However, high-altitude residents have low rates of preeclampsia 
compared to other populations at the same altitudes. Such population differences 
are due, at least in part, to differences in maternal vascular responses to pregnancy. 
It was hypothesized that natural selection acting on hypoxia-inducible factor 
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(HIF)-targeted or -regulatory genes has enabled maternal vascular adaptation 
to pregnancy in long-resident high-altitude groups. Earlier studies support this 
hypothesis and demonstrate that the potent genes can be differentially regulated 
between adaptive and less adaptive populations. Moore et al. show that HIF-
targeted vasoconstrictor, endothelin-1 (ET-1), is differentially regulated by preg-
nancy in Andean vs. European residents at high altitudes. Andeans, who live longer 
at high altitude, show normal, pregnancy-associated fall in ET-1 levels; whereas, 
Europeans have higher ET-1 levels and little pregnancy-associated change, like in 
preeclamptic women. Another hopeful study revealed that high-altitude Tibetans, 
who have lived the longest at high altitude, can share similar genotypic and allelic 
frequencies of adaptive variants with sea level Sojourners who undergo acclimatiza-
tion on ascent [8–10].
This led to the question that, if lowlanders on ascent have the ability to acquire 
allele and genotype frequency as in adaptive native individuals, can preeclamptic 
women undergo acclimatization, and can it be used as a predictive marker for the 
disease.
3. From preeclampsia to normal pregnancy: the hidden adaptation!
There are a very large number of both prospective and retrospective studies 
investigating the preeclampsia recurrence rate, with different sample sizes, target 
populations, study designs, and main outcome measures, resulting in contrasting 
conclusions. Yet, maternal and perinatal outcomes in the subsequent pregnancy are 
generally better than in the first; most women will not have recurrent preeclamp-
sia, and those who do usually will give birth at a greater gestational age compared 
with their index birth. Even though, women who have experienced a pregnancy 
complicated by preeclampsia, including their caregivers, undoubtedly have a fear of 
recurrence and should be counseled about their reproductive future. Many of these 
mothers and babies are at increased risk of severe adverse outcomes that include 
acute renal or hepatic failure, antepartum and postpartum hemorrhage, stroke, 
maternal death, intrauterine growth restriction, and perinatal death. Long-term, 
the burden of preterm birth is immense, particularly in terms of neurodevelop-
mental impairment, impaired learning, cerebral palsy, and need for special care 
resources [11].
Another evidence for the hidden adaptation is the ability of the placenta to sur-
vive the oxidative stress. Uterine artery Doppler studies are proposed to be abnor-
mal in the second trimester of pregnancy because of increased vascular resistance 
indicating failed remodeling of the vessels of the intervillous space. About half of 
women with abnormal uterine artery Doppler findings go on to have preeclampsia, 
preterm birth, or pregnancies complicated by IUGR, while, the other half go on to 
normal outcomes. Besides to the Doppler scans, biochemical markers, like reduced 
circulating ascorbate, increased concentrations of nitric oxide synthase, and AT1 
angiotensin receptor inhibitors, show evidence of oxidative stress both in women 
with or without abnormal uterine artery velocimetry. These markers are present 
regardless of whether the pregnancy proceeds to IUGR, preeclampsia, or a normal 
outcome.
These findings support the concept that poor placentation (Stage 1 of the model) 
alone is not sufficient to cause preeclampsia, and that there are other factors that 
adjust the physiological wheel of oxidative stress toward adaptation and normal 
pregnancy or toward preeclampsia (stage 2 of the model) [12]. In other words, it 
appears that the placenta starts as preeclamptic, and then somehow overcomes the 
oxidative stress and continues the placentation normally. This raises many questions 
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on what are the hidden mechanisms that enable the placenta to survive the oxidative 
stress and overcome the disease? What could happen in a subsequent pregnancy 
that renders them to be protected? Why the placenta from normal pregnancies 
survives the oxidative stress?
4. Hypoxia and natural selection
It is known that hypoxic microenvironment acts as a stress-induced mutagenesis 
by increasing genetic instability in human cell through highly regulated genetic 
mechanisms. The stabilization of HIF, the master transcriptional factor in hypoxia, 
down-regulates the major DNA repair mechanisms; mismatch repair and homolo-
gous recombination. This leads to a switch from the high-fidelity repair mechanisms 
to the error-prone mutagenic non-homologous end joining mechanisms, which 
result in a high degree of genetic variability. In earlier study, our findings revealed 
that genetic variability in periods of high hypoxic pressure in preeclamptic samples 
was more confined to certain genomic loci, in particular the HIF master regulators 
of hypoxia, compared to normal pregnancy [3, 13].
Different scenarios of genetic variability under stressful condition of hypoxia are 
proposed, and represent the basis for natural selection and adaptation. Figure 1 shows 
Figure 1. 
The degree to which the genes can be reprogrammed by mutations can be termed genetic flexibility [14]. 
Genetic variability permits flexibility and survival of a population in the changing environments. Here, the 
genetic variability is represented by circles. The dots in the circles are the number of genetic variants in a 
particular gene. The more the variants are, the highest is the genetic flexibility. (a) Different genes in the same 
individual with the same degree of stressful condition. Gene x shows a larger circle with more variants, and this 
may indicates that gene x is more influential at a particular stressful condition, and probably is more affected 
by the signals of that particular condition. (b) The same gene in different individuals under the same extreme 
condition. Individual 1 with a larger circle of genetic variability is more flexible and have higher chance to 
adapt under the certain condition than 2 and 3. Individuals 2 and 3 are either less flexible due to different 
reasons, or (c) may undergo a previous acclimatization experience that renders them to show a less degree of 
variability. In (c), gene x is in the same individual, but the larger circle is showing genetic variants in the first 
exposure to stressful microenvironment (hypoxia), followed by the second, and the third exposure. The decrease 
in the number of genetic variants in subsequent exposures reflects the stress relief, and probably acclimatization.
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dotted circles that represent the flexibility of hypoxia pathway genes under stressful 
conditions. The dots represent the genetic variants or mutations. The more flexible the 
gene is, the larger the circle of genetic variability, and thus the higher chances for natu-
ral selection to the fittest variants. This can predict the possible path of evolutionary 
events, and the possible roles of the genes with larger circles under stressful conditions.
In a previous report, we showed that preeclamptic samples had higher genetic 
variability in the key regulators of hypoxia pathway genes like EPAS1 and EGLN1 
compared to normal pregnancy, which indicates that they were under a high level 
of stress. We also hypothesized that the high genetic variability that are reflected 
by the high number of mutations in preeclamptic samples can be considered as a 
“positive response” toward adaptation by increasing the chance of having adap-
tive mutations, yet they are still evolutionary late compared to controls. In other 
words, normal pregnancy has higher rate of fixation to the adaptive variants 
compared to preeclampsia, and this can be the reason for the delay in the process 
of adaptation in some types of preeclampsia [3].
5. Genetic association studies and preeclampsia
Genome-wide linkage studies of preeclampsia and pregnancy-induced 
hypertension have identified different loci associated with preeclampsia that 
segregate with different populations: on 4q (between D4S450-D4S610 markers, 
found in Australia), 2q23 (between D2S112-D2S151 markers, Australia, NZ), 2p13 
(D2S286, Iceland), 2p25 (D2S168, Finland), 9p13 (D9S169, Finland), and 10q22 
(Netherlands). Additional loci are expected to exist in preeclamptic patients with 
certain complications, such as the locus 12q in patients with hemolysis, elevated 
liver enzymes, and low platelets (HELLP) syndrome [15–18].
Candidate genes studies have provided evidence for an association with pre-
eclampsia, frequently with inconsistent results. One of the common candidate 
genes is endothelial nitric oxide synthase gene (eNOS) on 7q36, which is responsible 
for nitric oxide production in endothelial cells. The endothelial dysfunction in 
preeclampsia reveals a strong association with eNOS polymorphisms. However, 
several other genome scans could not confirm this association. Another study found 
an evidence of moderate association with an increased risk for preeclampsia in 
women having mutations in coagulation factor genes; F5 Leiden (rs6025, G1691A), 
and the prothrombin (F2) gene (rs1799963, G20210A). This evidence may explain 
the association of the disease with coagulation disorders. Several studies found 
associations between renin-angiotensin-aldosterone system with gestational 
hypertension and preeclampsia. Earlier linkage studies found an association with 
angiotensinogen (AGT) locus, on 1q42-43 and the risk for hypertensive disease in 
different sets of population. They also found an association between specific allele 
AGT (T235, rs699) with essential hypertension and preeclampsia. Angiotensin 
converting enzyme (ACE) along with AGT receptor 1 (AGTR1) were also found to 
have a role in the pathogenesis of the preeclampsia. Another candidate gene that 
link preeclampsia to the risk of hypertension is the T allele (C677T) of the methy-
lenetetrahydrofolate reductase (MTHFR) gene [19–23].
To conclude, no single gene or chromosomal locus currently known can explain 
the pathogenesis of preeclampsia. This indicates that preeclampsia is a polygenic 
disorder, and it reflects an integrated pathophysiological process of insufficient 
adaptation, not only in the placenta, but also in other tissues and organs. On the 
other hand, the geographical distribution of candidate genes and loci in associa-
tion with the pathogenesis of preeclampsia may reflect the interaction between the 
different environments and the gene pool of populations.
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6. Adaptive polymorphisms of hypoxia genes
Here, we discuss some of the known genetic polymorphisms that influence 
maternal vascular adaptation in normal pregnancy and preeclampsia, high-altitude 
adaptation, and adaptive variants in healthy exercise. These genetic changes affect 
the protein activity and production, and can be set as early predictive markers for 
adaptation.
6.1 Endothelial nitric oxide synthase (eNOS): (rs1799983, G894T, Glu298Asp)
Healthy pregnancy is associated with enhanced endothelium-dependent vasodi-
lation in the brachial artery, a response mediated by NO. These changes are thought 
to be an important physiological adaptation that accommodates the increased 
circulating blood volume and cardiac output during pregnancy. A common poly-
morphism of the eNOS gene is G894T in the mature protein that has been associated 
with the differences in endothelium-dependent dilation at 12-week gestation. There 
are several reports on the association between eNOS 894T allele polymorphism and 
PE susceptibility. They also provide a potential mechanism linking eNOS polymor-
phism with the prediction of cardiovascular disorders and pulmonary edema in 
which NO bioactivity is impaired [24–26].
In high-altitude adaptation, previous studies showed that the eNOS G894T 
polymorphism contributed to physiology and pathophysiology of humans at 
high altitude by regulating the production of NO. The 894G allele carriers and 
GG genotype might be a beneficial factor for HA adaptation through enhancing 
the level of NO, and 894T allele and heterozygous G/T of the 894G/T variant are 
associated with the susceptibility to high-altitude pulmonary edema (HAPE) at 
Qinghai-Tibet. In acclimatization to high altitude, NO levels increase dramatically 
above the baseline levels, while visitors ill with high-altitude pulmonary edema at 
the time of the study or in the past, have NO levels were lower than those of their 
healthy counterparts. Highland indigenous populations like Tibetans have high NO 
levels in the lung, plasma, and red blood cells that were at least double the levels 
that can be found in other populations regardless of altitude. With respect to NOS3 
G894T and its relation to athletic performance or status, the over-representation of 
the GG genotype and G allele in all athletes suggests that the G894 allele may favor 
many types of sports [27, 28]. This supports the adaptive function of 894G allele 
and genotype.
Probably adaptive: 894G allele; less adaptive: 894 T allele
6.2 Angiotensin converting enzyme (ACE): (rs4646994, ACEI/D)
Circulating angiotensin I-converting enzyme (ACE) exerts a tonic regulatory 
function in circulatory homeostasis, through the synthesis of vasoconstrictor 
angiotensin II. ACE I/D (insertion/deletion) polymorphism is associated with ACE 
level. The presence (insertion, I allele) rather than the absence (deletion, D allele) 
of a287 bp Alu sequence insertion fragment is associated with lower serum and 
tissue ACE activity and thus lower angiotensin II production. The D allele of the 
ACE I/D polymorphism along with higher ACE levels were over-represented in Han 
Chinese who was afflicted with AMS. On ascent to extreme altitudes, the I allele 
of the ACEI/D polymorphism may tend to have more sufficient/efficient acclima-
tization and consequently have less risk of developing AMS. It was hypothesized 
that the pioneer lowlanders who migrated to high altitude might have the I-related 
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genotypes (the II or ID genotype) as an “inner predisposition” to overcome altitude 
illnesses during migration and adaptation and finally was able to settle at high alti-
tude permanently. However, some evidence shows that they may gain their adapta-
tion through the long period of settlement. Along with elite mountaineers, the I 
allele has been associated with some aspects of endurance performance in Marathon 
runners, rowers, cyclists, handball players, and others in different population. In 
the prediction of the disease, it was shown that the ACE D allele leads to increased 
expression of plasminogen activator inhibitor-1 (PAI-1), which can increase the risk 
of preeclampsia and thrombotic events and enhances the production of angiotensin 
II from angiotensin I [29, 30].
Probably adaptive: ACE I allele; less adaptive: ACE D allele
6.3 Vascular endothelial growth factor (VEGFA): (rs3025039, C 936T)
Vascular endothelial growth factor (VEGF) is a major angiogenic factor that acts 
as a regulator of endothelial cell proliferation and vascular permeability. VEGF has 
been shown to be markedly up-regulated in hypoxic conditions. A common poly-
morphism of VEGFA is 936 C>T (rs3025039). The carriers of the 936T allele have 
lower VEGF plasma level by one-third of non-carriers. In a comparison between 
two groups of lowlanders on ascent to high altitude; those with 936T allele have a 
decreased risk of acute mountain sickness. In acute exercise, VEGF levels increases 
in sedentary individuals “less adaptive,” whereas exercise adaptation attenu-
ates VEGF gene expression in human skeletal muscle in trained “well adaptive” 
individuals. Both findings appear to be related in preeclamptic women, where the 
increased VEGF level is accompanied by the C allele of VEGFA. Thus, it is possible 
that the T allele associates with the maintenance of normal pregnancy and may 
confer a protective effect against the development of preeclampsia and is consistent 
with the concept of having the T allele and low VEGF levels among women with 
normal, uncomplicated pregnancies [31].
Probably adaptive: 936T allele; less adaptive: 936 C allele
6.4 HIF-2α/EPAS-1: high-altitude adaptive gene
It was recently shown that the gene encoding HIF-2α/EPAS-1 represents a key 
mutated gene in the adaptation of Tibetan populations at high altitudes. Although 
it is highly similar to HIF-1 and has the potential to bind and mediate many of 
the same genes as HIF-1, its biological actions in response to hypoxia are distinct 
from those of HIF-1. By now, several of these HIF-2 mediated processes have been 
implicated in the human response to high-altitude exposure including erythropoi-
esis, iron homeostasis, metabolism, and vascular permeability, which are perturbed 
in preeclampsia. HGB-decreasing allele of EPAS1 is under very strong positive 
selection in Tibetans and is strongly associated with Hb, red cell count, and hema-
tocrit. Although there is no association between HIF-2α/EPAS-1 polymorphisms 
and preeclampsia in the literature, few studies found up-regulated expression of 
HIF-2α in preeclampsia. In earlier work, we discussed the association between 
EPAS1 polymorphisms and preeclampsia. Based on the strong positive association 
signal of adaptation in Tibetans, I emphasized on the role of EPAS1 in preeclampsia, 
and suggest and for the first time that the mutated EPAS1, has to be considered as 
a major player for placental adaptation in normal pregnancy and preeclampsia. 
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Further experimental studies are needed to confirm the biological function of 
EPAS-1 in normal pregnancy [3, 32–34].
6.5 Methylenetetrahydrofolate reductase (MTHFR) (rs1801133, A222 V, C677T)
The effects of MTHFR on preeclampsia are of great interest to researchers in 
the field. MTHFR plays a key role in homocysteine metabolism. Tibetans have an 
increased frequency of the homocysteine-decreasing allele of rs1801133 at the 
MTHFR locus more than other individuals from Eastern Asian ancestry. The homo-
cysteine level in Tibetans is even lower than in Han, who lives at the same highlands 
of Tibet’s but for shorter period. This renders them to be less adaptive compared to 
Tibetans. On the other hand, several studies found significant association at this 
locus with PE. The gene promoter of MTHFR is found to be hypermethylated in 
preeclamptic women, and this results in a high level of homocysteine. The same can 
be found in high-altitude sickness as a result of mal adaptation [35, 36].
7. Adaptive or less adaptive
Looking for adaptive variants is the “half-full” interpretation for the pre-
diction of a multiple disorder like preeclampsia. The genetic scan can include 
adaptive genes and polymorphisms, their functional importance, i.e., effect on 
enzyme activity and production, their protective effect, i.e., protective from/at 
risk of cardiovascular disorders, pulmonary edema, thrombosis, thrombophilia, 
retinopathy, etc.
Earlier predictive markers for preeclampsia are believed to be in the first tri-
mester, but it could be earlier even before the pregnancy period. Exercise stress test 
can be done to measure the levels of oxidative stress during and after the exercise to 
predict the possible response of the body. Allele and genotype frequencies of adap-
tive variants before the pregnancy, gene expression during and after the exercise 
can also be studied. In short, women who are less adaptive in their exercise have the 
potentials to develop preeclampsia. The same in high-altitude adaptation, women 
who suffer on ascent to high altitude are more likely to be preeclamptic.
“Adaptive or less adaptive” can be simply the final result of genetic tests that 
predict the disease, recurrence, and possible complications. DNA analysis for 
potential genetic markers may serve to screen for the risks of preeclampsia/eclamp-
sia and other adverse pregnancy outcomes. Those with positive adaptive status 
are considered to be at decreased risk of developing preeclampsia. Certain genetic 
polymorphisms are attributed with certain adverse pregnancy outcomes.
8. Ischemic reperfusion stress: adaptation or insult
In 1964, Martin et al. show that maternal blood flow of spiral arteries in the 
intervillous space is intermittent in all normal pregnancies, and they wondered if 
this intermittency is a mechanism for regulating maternal placental blood flow. 
In preeclampsia, it is believed that the process of intermittent placental perfusion 
(ischemic/reperfusion) secondary to deficient trophoblast invasion is a key inter-
mediary step in the pathogenesis of preeclampsia.[37, 38].
However, the process of ischemia and reperfusion is well known to be used in 
clinical settings in the area of coronary heart diseases to protect the heart from the 
harmful effects of subsequent, prolonged ischemia by the exposure of tissues to 
certain degrees of intermittent periods of hypoxia and reoxygenation. The process 
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termed ischemic preconditioning has been demonstrated in patients with cardio-
vascular disease as well as in many other organs. The process, termed ischemic 
preconditioning, has been demonstrated in patients with cardiovascular disease as 
well as in many other organs. Recent evidence suggests that there are actually two 
distinct types of protection afforded by preconditioning, acute and delayed pre-
conditioning. The protective effects of acute preconditioning are protein synthesis 
independent in short intervals, while the effects of delayed preconditioning require 
protein synthesis in tissues subjected to prolonged ischemia. Delayed precondition-
ing appears to be an adaptation response that is dependent on altered gene expres-
sion as well as the synthesis of new proteins, including NO pathway.
It has been postulated that hypoxic preconditioning might occur normally in 
placentae that develop at high altitude. Laboring placentae at 3100 m have little or 
no oxidative stress at the time of delivery, suggesting greater resistance to ischemia-
reperfusion. Unlike pregnancies at sea level subjected to labor display evidence of 
oxidative stress. In fact, exercise can be considered as a form of remote ischemic 
conditioning, in which the stimulus is distant from the organ being protected. 
Remote ischemic conditioning has been termed “exercise in a device,” especially 
suited for patients who are unable or unwilling to work out [39–41].
The question is can we consider the intermittency of maternal blood flow as 
a regulatory mechanism for natural hypoxic preconditioning that can occur in 
placentae from high altitude, and can it be the answer for the earlier question from 
the 1960s.
8.1 Genetics and ischemic preconditioning
Ischemic preconditioning reprograms the response to ischemic injury via tran-
scriptional changes that resemble evolutionarily conserved responses to decreased 
blood flow and oxygen availability. The response to ischemia alters gene expression 
and induces cellular adaptations and hypoxia tolerance. One of the regulatory 
mechanisms is the genetic reprogramming through microRNAs. MiRNA-144 and 
-21 have been associated with ischemic preconditioning and normal pregnancy, and 
can be considered as adaptive miRNAs.
MicroRNA-144 is a circulating effector of remote ischemic preconditioning. 
Systemic release of microRNA-144 plays a pivotal role in inducing early and delayed 
cardioprotection with improved functional recovery and reduction in infarct size. 
Comparably, miRNA-144 was down-regulated in severe preeclampsia during the 
early stages of pregnancy, which supports the maladaptive nature of the disease.
MicroRNA-21 stimulates angiogenesis by inducing VEGF production. MiRNA-
21 expression is required for local and remote ischemic preconditioning in multiple 
organ protection, including kidneys, heart, liver, and lungs. In sport genomics, 
several studies support the protective role of miRNA-21 as an important regulator 
of exercise adaptation and in the protection of many disorders including cardiovas-
cular disorders. In normal pregnancy, miR-21 has been shown to enhance tropho-
blast proliferation and invasion via modulating the nodal signaling pathway, and 
involve in angiogenesis process positive regulator of VEGF-A and HIF-1α. Yet, the 
persistent of miRNA-21 angiogenic signal can be deleterious [42–46].
9. Structural adaptations of the placenta
The prominent histological changes represent the structural adaptations for pla-
cental ischemia, which creates a hostile environment for the preeclamptic placentae. 
A number of these histopathological changes have been described; namely placental 
Prediction of Maternal and Fetal Syndrome of Preeclampsia
10
infarcts, increased syncytial knots, hypovascularity of the villi, increased cytotro-
phoblastic proliferation, thickening of the sub-trophoblastic basement membrane, 
obliterated enlarged endothelial cells in the fetal capillaries, and atherosis of the 
spiral arteries in the placental bed. The volume of the intervillous space and the 
terminal villi are also decreased in proportion to the degree of preeclampsia. Some 
of the histological features like syncytial knots, cytotrophoblastic proliferation, 
thickening of sub-trophoblastic basement membrane, and hypovascular villi were 
observed in the placentae of normotensive women in varying degrees yet within 
normal limits [47].
Placental infarcts are small yellowish-white deposits of fibrin (a fibrous pro-
tein) of the placenta caused by the inadequate blood supply. They occur normally 
in the placenta as pregnancy progresses, and account about 25–30% of term normal 
pregnancies. The fetus usually is not affected by infarction of the placenta, unless 
the process is extensive. However, infarcts are found in nearly all cases of moderate 
or severe PIH. They are strongly associated with pregnancy-induced hypertension 
(PIH) and with growth-restricted babies. Moreover, several studies have found a 
direct correlation between the degree of PIH and the amount of infarction of the 
placenta. At molecular levels, plasminogen activator inhibitors (PAI-1/PAI-2), 
which regulate fibrinolysis, could be responsible for the very high levels of fibrin 
deposition in the intervillous space and the placental infarction observed in these 
pregnancies. The hypofibrinolytic genotypes 4G/4G and A/A of the PAI-1 gene are 
associated with the occurrence of mild preeclampsia. The insertion/deletion PAI-1 
4G/5G polymorphism (rs1799889) was also found to have a significant association 
with preeclampsia [48, 49].
Acute atherosis is characterized by subendothelial lipid-filled foam cells, fibri-
noid necrosis, and perivascular lymphocytic infiltration. This lesion is generally 
confined to non-transformed spiral arteries and is frequently observed in patients 
with preeclampsia. In early-onset preeclamptic patients, the polymorphisms in the 
regulator of G protein signaling 2 gene (RGS2) 3′UTR (C1114G, rs4606) of CG or 
GG genotype is more frequent in decidual spiral arteries in women with acute ath-
erosis (resembling early stage of atherosclerosis). PIA-1, as an important regulator 
within the fibrinolytic system, has also been shown to be a risk indicator for venous 
and arterial thrombosis [50, 51].
Retroplacental hematoma (placental abruption) is having bleeding behind 
the placenta. This happens when the placenta starts separating prematurely due 
to bleeding and instability of uteroplacental vessels. The maternal MTHFR C677T 
polymorphism was found to be a risk factor for placental abruption. This agrees 
with the association of hyperhomocysteinemia with placental abruption [52, 53].
Syncytial knots: For oxygen requirement, the syncytium depends on the 
maternal blood flow to the intervillous space through the uteroplacental circulation. 
Reduced uteroplacental blood flow in hypertension may result in hypoxic damage 
to the syncytium. The damaged syncytium stimulates syncytial nuclear prolifera-
tion leading to syncytial knots formation. In an attempt to replace the degenerated 
syncytium, the cytotrophoblast cells undergo proliferation. Increased numbers 
of syncytial knots have been reported in placentae of pregnancies complicated by 
preeclampsia, probably to be induced by hypoxia. Syncytins 1 and 2 genes play a 
crucial role in trophoblast fusion stage of syncytial knot formation [47, 54].
10. The cross talk between syncytiotrophoblast and other remote organs
Throughout pregnancy, the cross talk between the placenta and other parts 
of the body is mainly relying on messages released from the syncytium into the 
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maternal circulation. There are extracellular vesicles often referred to as syncytio-
trophoblast extracellular vesicles (STBEVs) due to their syncytiotrophoblast cell 
of origin. They are believed to play an important role both in normal and dysfunc-
tional pregnancies. They are released in form of exosomes, microvesicles, and apop-
totic bodies that carry many syncytiotrophoblast derived factors such as mRNA, 
miRNA, proteins, and lipids. This gives a potentially rich source of biomarkers in 
complications involving placental dysfunction [55, 56].
Vascular endothelial cells: In preeclampsia, there is an increased release of 
placental STBEVs into the maternal circulation. It has been suggested that release 
of factors from the placenta in response to ischemia results in endothelial dysfunc-
tion of the maternal circulation. As a result, an imbalance of anticoagulation and 
procoagulation forces is found in preeclampsia as increases in proteins of the 
coagulation cascade, proangiogenic and antiangiogenic imbalance resulting in high 
sflt-1 levels that inactivate VEGF function, increased adhesion cell molecules are 
also significantly elevated including VCAM-1, ICAM-1, and E-selectin. An example 
of angiogenic imbalance is the syncytial knots that are enriched with sFlt1 protein. 
At least 25% of the measurable sFlt1 in the third-trimester maternal plasma is 
bound to circulating placental microparticles. The free detached syncytial knots 
are loaded with sFlt1 protein and mRNA. These findings suggest that STBEVs may 
cause endothelial damage and contribute to the endothelial dysfunction [57].
Paranchymal organs: In general, the histological changes, mainly in eclamptic 
phase of preeclampsia, are hemorrhagic and thrombotic in nature. They are found 
in the main parenchymatous organs: liver, kidneys, placenta, brain, and adrenals. 
The liver lesions, when present, take the form of irregular, focal subcapsular, 
and intraparenchymal hemorrhages. On histologic examination, there are fibrin 
thrombi in the portal capillaries and foci of hemorrhagic necrosis. The kidney 
lesions are variable. The glomeruli show marked swelling of endothelial cells, 
amorphous dense deposits on the endothelial side of the basement membrane, 
and mesangial cell hyperplasia. Immunofluorescent studies show an abundance of 
fibrin in glomeruli. In advanced cases, fibrin thrombi are present in the glomeruli 
and capillaries of the cortex. If widespread and severe, these thrombi may produce 
complete destruction of the cortex in the pattern referred to as bilateral renal 
cortical necrosis. The brain may have gross or microscopic foci of hemorrhage along 
with small vessel thrombosis. Similar changes are often found in the heart and the 
anterior pituitary [58].
At molecular level, circulating STBEVs can directly affect these remote organs 
(Figure 2). An example of this is the STBEVs uptake by the primary human 
coronary artery endothelial cells and the transfer of placenta specific miRNAs 
from STBEVs inside these recipient cells. The transferred miRNAs were functional, 
causing a downregulation of specific target genes, including the PE associated 
gene fms related tyrosine kinase 1 (FLT1). This suggests the ability of the placenta 
for endothelial reprogramming that may underlay the increased risk of cardio-
vascular disease reported for women with preeclampsia later in life. In kidneys, 
renal ischemic preconditioning up-regulates the expression of microRNA-21 in 
serum extracellular vesicles of exosomes in kidney and remote organs. This results 
in decreased apoptosis and reduced proinflammatory cytokines production in 
multiple organs including kidneys, heart, liver, and lungs. Another example is the 
role of STBEVs in thrombi formation. STBEVs released from preeclamptic placenta 
exhibit increased procoagulant tissue factor activity. Tissue factor is the primary 
initiator of coagulation in vivo. The increased numbers of circulating STBEVs 
in the blood of women with preeclampsia, along with the greater expression of 
tissue factor on preeclampstic STBEVs would be expected to comprise a substantial 
intravascular pro-thrombotic stimulus. A majority of deep venous thrombosis 
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occur within the valve pockets of deep venous valves that are exposed to “periods 
of stasis” and low oxygen levels, resembling the I/R oxidative stress. Venous valves 
have adapted to this phenomenon by expressing higher levels of anticoagulants 
thrombomodulin and endothelial cell protein C receptor, which are both decreased 
in preeclampsia [59–61].
To conclude, the high degree of concordance between placental lesions and gene 
expression across different subtypes of preeclampsia, reflects the importance of 
appropriate communication in successful pregnancy [62, 63].
11. Evolutionary steps: from preeclamptic cells, cancer to adaptive cells
Preeclamptic cells are genetically late compared to cancer cells, and this is 
probably the reason behind their protection from cancer. For example, angiogenesis 
are balanced in normal cells, and shift to the lift in preeclampsia and to the right 
in cancer cells and adaptive cells. The shift of preeclamptic cells from the left to 
the right can take longer time  (Figure 3). Longer prospective studies show that 
preeclamptic women can lose their protective advantage by time, while adaptive 
individuals, according to the evolutionary steps, can show better protection than 
preeclamptic cells [65]. Normal cells can avoid cancer and jump to adaptive status 
by gradual adaptation or preconditioning. This is why normal multiple pregnancies 
are naturally protected from cancer and other oxidative stress disorders, due to 
their intermittent exposure to hypoxia that act as natural ischemic preconditioning. 
Accordingly, both preeclamptic cells and adaptive cells are protective against cancer, 
but for different reasons. In a different context, cancer cells, due to their high 
cellular turnout and high evolutionary rate, have a higher ability to gain mutations, 
Figure 2. 
The role of syncytiotrophoblast extracellular vesicles (STBEVs) in the cross talk between the placenta and 
other tissues and organs include exosomes, microvesicles, apoptotic bodies, and syncytial knots. Adequate blood 
flow from a limited number of EVs are shed from the placenta into the maternal circulation, while increased 
number of STBEVs are shed from preeclamptic placenta. The cargo of STBEVs including microRNAs, mRNAs, 
proteins, lipids, and glycans may be “planned” by the placenta. This cargo controls gene expression in vascular 
endothelial cells and other tissues and organs. STBEVs contents and deportations are controlled by the placental 
hypoxia. In preeclampsia, high levels of hypoxia lead to reduce syncytin-1 expression, and thus increased 
syncytial knots deportation [64].
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and thus have a high probability for adaptive mutations. This can be used to study 
the protective function of adaptive variants in pregnancy and preeclampsia under 
different stressful conditions.
12. Conclusion
Future genetic studies are required for assaying additional adaptive variants 
near the candidate, HIF-targeted and -regulatory genes for testing functionality, 
and verify the existence of natural selection [9]. Such studies present a novel and 
relatively unexplored approach that enable the normal cells to adapt to their scarce 
microenvironment to the highest possible extent. No matter of the reasons that lead 
to preeclampsia, which are probably different, the advanced integrated biologi-
cal system of genetic and epigenetic adaptive polymorphisms can “vaccinate” the 
body against the detrimental consequences and complications of the disease, and 
can reflect the ability of the body for survival and recovery. Methods of inducing 
natural adaptive mechanisms, like in ischemic preconditioning, has been attempted 
in clinical practice in the area of coronary heart disease in an attempt to limit the 
injury caused to the heart via ischemia and reperfusion injury. Such injury would 
occur when a patient has an acute myocardial infarction followed by reperfusion 
by either percutaneous coronary intervention or thrombolysis. Although, placental 
preconditioning was suggested to occur as an adaptive response to the hypobaric 
hypoxia at high altitudes, the area of placental preconditioning in clinical practice 
is yet to be explored. At molecular levels, adaptation to hypoxia can enhance the 
ability of the placenta to acquire genetic adaptive experience resulting in a stress 
relief, protection, and probably recovery in subsequent pregnancies. The messages 
released from the placenta into the maternal circulation transfer the genetic experi-
ence throughout the body. It can dramatically modify the histological picture in the 
placenta and other remote organs, and modulate the function of these organs.
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Figure 3. 
Evolutionary steps from preeclamptic cells, normal cells, cancer cells, and adaptive cells.
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